Literature DB >> 33283019

In vitro characterization of chemokine-loaded liposomes.

Angel J Rubio1, Xuemei Zhong2, Tyrone M Porter3,4.   

Abstract

The recent emergence of immunotherapies is transforming cancer treatments. Although many cancer immunotherapies are finding enormous success for treating hematologic tumors, a major obstacle for the treatment of solid tumors is localizing immune cells to the tumor site. Therefore, we have developed a technology that is capable of directing immune cell migration. Specifically, we have packaged chemokines, signaling molecules that promote immune cell migration, inside polyethylene glycol decorated-liposomes. The release profiles of chemokines and other large molecules from the liposomes have been examined in serum-containing media. We have demonstrated that the liposomes are able to release chemokines to induce immune cell migration. Additionally, these liposomes have been shown in vitro to limit cancer cell growth through increased immune cell recruitment. This strategy of encapsulating chemokines within liposomes paves the way for additional cancer immunotherapies and chemokine-based therapies.

Entities:  

Keywords:  Nanotechnology; chemokine delivery; immunotherapy; liposomes; peptide

Year:  2019        PMID: 33283019      PMCID: PMC7716865          DOI: 10.1080/23312025.2019.1662931

Source DB:  PubMed          Journal:  Cogent Biol        ISSN: 2331-2025


  22 in total

1.  CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity.

Authors:  K Mark Ansel; Ruth B S Harris; Jason G Cyster
Journal:  Immunity       Date:  2002-01       Impact factor: 31.745

Review 2.  Death by stress: natural IgM-induced apoptosis.

Authors:  H P Vollmers; S Brandlein
Journal:  Methods Find Exp Clin Pharmacol       Date:  2005-04

Review 3.  The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors.

Authors:  D Needham; M W Dewhirst
Journal:  Adv Drug Deliv Rev       Date:  2001-12-31       Impact factor: 15.470

Review 4.  CAR T-cell Therapy: A New Era in Cancer Immunotherapy.

Authors:  Androulla N Miliotou; Lefkothea C Papadopoulou
Journal:  Curr Pharm Biotechnol       Date:  2018       Impact factor: 2.837

5.  Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans.

Authors:  Stephanie Brändlein; Tina Pohle; Nele Ruoff; Ewa Wozniak; Hans-Konrad Müller-Hermelink; H Peter Vollmers
Journal:  Cancer Res       Date:  2003-11-15       Impact factor: 12.701

Review 6.  A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics.

Authors:  Stephanie D Steichen; Mary Caldorera-Moore; Nicholas A Peppas
Journal:  Eur J Pharm Sci       Date:  2012-12-20       Impact factor: 4.384

7.  Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth.

Authors:  Upendra K Kar; Minu K Srivastava; Asa Andersson; Felicita Baratelli; Min Huang; Valerie A Kickhoefer; Steven M Dubinett; Leonard H Rome; Sherven Sharma
Journal:  PLoS One       Date:  2011-05-03       Impact factor: 3.240

8.  Isolation of mouse peritoneal cavity cells.

Authors:  Avijit Ray; Bonnie N Dittel
Journal:  J Vis Exp       Date:  2010-01-28       Impact factor: 1.355

9.  A novel IgM-H-ficolin complement pathway to attack allogenic cancer cells in vitro.

Authors:  Xiaoying Lei; Chaoxu Liu; Kazem Azadzoi; Cuiling Li; Fan Lu; An Xiang; Jianbin Sun; Yanhai Guo; Qingchuan Zhao; Zhen Yan; Jinghua Yang
Journal:  Sci Rep       Date:  2015-01-16       Impact factor: 4.379

Review 10.  An Overview of B-1 Cells as Antigen-Presenting Cells.

Authors:  Ana F Popi; Ieda M Longo-Maugéri; Mario Mariano
Journal:  Front Immunol       Date:  2016-04-11       Impact factor: 7.561

View more
  1 in total

Review 1.  Inducible Tertiary Lymphoid Structures: Promise and Challenges for Translating a New Class of Immunotherapy.

Authors:  Shota Aoyama; Ryosuke Nakagawa; James J Mulé; Adam W Mailloux
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.